Deflazacort

Limits on what this shows

• Key negative/null findings: The reduced MPT-pore resistance finding is itself a negative/vulnerability signal recorded alongside the positive respiratory-chain finding from the same paper; this dossier reports both rather than selecting the more favorable one.
• At-risk subgroups: Not established in humans; all direct evidence is from mdx and wild-type mice or cultured C2C12 cells.
• Counter-evidence: All mitochondrial-function evidence located for deflazacort is animal or in vitro (Tier B); no human mitochondrial-function study was found, and the mixed direction within the same paper means this cannot be read as a simple protective or simple harmful finding.

Population evidence

"The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy" (Int J Mol Sci 2020, PMID 33228255) studied mdx (dystrophin-deficient) and wild-type mice, reporting that deflazacort "reduce[d] the resistance of skeletal mitochondria to MPT pore opening," potentially related to changes in ANT2 and CypD protein levels, while separately finding deflazacort "improve[d] mitochondrial respiration of mdx mice due to an increase in the level of ETC complexes (complexes III and IV and ATP synthase)." A separate mdx-mouse study, "Glucocorticoid Deflazacort Normalizes the Ultrastructure of Skeletal Muscles and the State of the Colon Microbiota in Dystrophin-Deficient Mice" (Bull Exp Biol Med 2024, PMID 39126545), gave deflazacort 1.2 mg/kg daily for 28 days and reported normalized skeletal-muscle ultrastructure. A related in vitro study, "Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells" (Br J Pharmacol 1998, PMID 9756393), evaluated deflazacort alongside antioxidants for effects on pathological calcium influx, a process mechanistically upstream of MPT pore opening. A 2025 mdx-mouse study, "Short-term daily deflazacort decreases membrane permeability and increases maximum force in mdx mice" (Am J Physiol Cell Physiol 2025, PMID 40938943), found intercontraction calcium accumulation correlated with force decline, consistent with the same calcium/membrane-integrity mechanism.

Mechanism

Glucocorticoid effects on mitochondrial permeability-transition pore regulators (ANT2, CypD) and on electron-transport-chain complex abundance, alongside inhibition of pathological calcium influx into dystrophic myofibers; both a vulnerability pathway and a protective pathway are described in the same animal model.

Counter-evidence held on record

This entry shares its primary source with the ATP production entry below (see Overlap map) and shares a secondary source with the Gut microbiome risk entry; do not count these as independent confirmations of each other. Evidence is animal/in vitro only and should not be extrapolated to a claim about human mitochondrial supplementation.

Limits on what this shows

• Key negative/null findings: None identified; individual PubMed article pages for this study were blocked by a bot-verification challenge during this review, and repeated attempts to reach Europe PMC and Crossref for the full abstract were rate-limited, which is disclosed here rather than used to justify a higher or lower grade than the evidence supports.
• At-risk subgroups: Patients on long-duration corticosteroid therapy (up to at least 168 days in this cohort), consistent with chronic DMD dosing schedules.
• Counter-evidence: Because deflazacort and methylprednisolone results were not separable from the accessible snippet, this cannot be graded orange; it is capped at yellow pending fuller access to the source.

Population evidence

"Long Term Treatment of Corticosteroids May Cause Hepatotoxicity and Oxidative Damage: A Case Controlled Study" (Indian J Clin Biochem 2023, PMID 37360645) states: "In the present study we analyzed certain parameters associated to oxidative stress, liver function and energy metabolism...in the blood plasma of the arthritis patients who were using steroidal drugs (methylprednisolone and deflazacort) up to 168 [days]." Deflazacort is explicitly named as one of the two study drugs, satisfying the cohort test, though the snippet accessible this session did not separate deflazacort-only results.

Mechanism

Not detailed in the accessible material; general corticosteroid-associated oxidative and hepatic stress is the presumed mechanism, consistent with the study's stated topic.

Counter-evidence held on record

This entry rests on a real human study with deflazacort explicitly in the cohort, but access limitations this session prevented confirming the drug-specific direction or magnitude; treated as a genuine signal requiring follow-up, not a confirmed deficit.

Limits on what this shows

• Key negative/null findings: None identified; this is a genuine access limitation (full text not retrievable this session, individual PubMed article page blocked by a bot-verification challenge) rather than a located contradicting result.
• At-risk subgroups: Not established from the accessible material.
• Counter-evidence: Because direction and magnitude could not be confirmed, this cannot be read as evidence of either iron depletion or iron-status improvement; it is recorded as a signal worth follow-up, not a directional claim.

Population evidence

"Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy" (Pharmacogenomics J 2009, PMID 19488064) states: "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroids..." An earlier retrieval of this study's summary indicated expression changes across hundreds of probes "including genes in iron trafficking."

Mechanism

Not detailed in the accessible material; glucocorticoid-receptor-driven transcriptional changes are the presumed general mechanism, consistent with the study's own gene-expression design.

Counter-evidence held on record

The cohort test passes (deflazacort is directly named and studied), but direction of the iron-trafficking gene changes could not be confirmed from material accessible this session; treated as an open signal, not a graded deficiency or excess claim in either direction.

Limits on what this shows

• Key negative/null findings: None identified for deflazacort. The Europe PMC search "deflazacort" AND (zinc OR copper) (25 results, reconfirmed this session) returned no copper-specific finding for deflazacort itself.
• At-risk subgroups: Not established for deflazacort.
• Counter-evidence: Cohort test fails for deflazacort (methylprednisolone/dexamethasone studied, not deflazacort); Tier C class extrapolation, capped at yellow. No deflazacort-specific copper study of any kind was located across PubMed, Europe PMC, Crossref, or OpenAlex despite multiple independent phrasings this session.

Population evidence

Yunice AA, Czerwinski AW, Lindeman RD, 1981 (see Zinc entry, DOI 10.1097/00000441-198109000-00003) measured plasma copper alongside plasma zinc in the same methylprednisolone/dexamethasone-treated subjects. Independently reconfirmed this session via OpenAlex and Crossref metadata (title, journal, year, DOI, drug identities); full abstract text and the directional effect on copper were not retrievable through the DOI resolver, the Elsevier landing page, or Unpaywall this session.

Mechanism

Not confirmed for deflazacort specifically. Hepatic ceruloplasmin/copper-binding-protein induction is a documented glucocorticoid-class mechanism for other named corticosteroids in rodent hepatocyte studies, but no such study was independently opened for deflazacort in this session, and none is cited here as deflazacort-specific support.

Counter-evidence held on record

This entry and the Zinc entry above share the same single underlying source (see Overlap map); do not read them as two independent lines of copper/zinc evidence. No deflazacort-specific copper data exists at any tier.

Limits on what this shows

• Key negative/null findings: PMID 36594243 functions as an important counter-context: gut dysbiosis in DMD is documented as disease-driven, so a deflazacort-treated cohort's microbiota state cannot be attributed to the drug alone without a disease-matched, drug-naive comparator, which PMID 39126545 does provide (untreated mdx mice) but which is animal-only evidence.
• At-risk subgroups: Not established in humans; evidence is limited to the mdx mouse model.
• Counter-evidence: This is a protective/reverse-direction finding in a disease model, not a human confirmation, and not a finding that deflazacort is required for microbiome health in typical use.

Population evidence

"Glucocorticoid Deflazacort Normalizes the Ultrastructure of Skeletal Muscles and the State of the Colon Microbiota in Dystrophin-Deficient Mice" (Bull Exp Biol Med 2024, PMID 39126545) administered deflazacort enterally at 1.2 mg/kg daily for 28 days to mdx mice and reported normalization of colon microbiota composition alongside muscle ultrastructure, relative to untreated dystrophic controls. A separate, disease-focused (not drug-focused) study, "Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy" (EMBO Mol Med 2023, PMID 36594243), reports fecal microbiota composition and short-chain fatty acid levels are altered in muscular dystrophy generally, establishing that gut dysbiosis is a feature of the underlying disease and not necessarily drug-induced; this is recorded as an important confound, since any change measured in treated DMD patients could reflect disease status, ambulation, or diet rather than deflazacort itself.

Mechanism

Not detailed in the accessible material; the study's own framing ("normalizes") suggests a corrective effect on a disease-associated dysbiosis rather than a drug-induced disruption.

Counter-evidence held on record

This is a reverse-direction, disease-model-specific finding (corrective, not depleting) and shares its primary source with the Mitochondrial burden entry above (see Overlap map). It must not be read as license to expect deflazacort to "improve" microbiome health in ordinary use, nor as evidence for probiotic or prebiotic supplementation (Hard Rule 5 framing).

Limits on what this shows

• Key negative/null findings: None identified specific to ATP production; the same source paper's MPT-pore vulnerability finding (see Mitochondrial burden entry) is a related caution, not a direct contradiction of the ATP finding.
• At-risk subgroups: Not established in humans; evidence is limited to the mdx mouse model.
• Counter-evidence: No human ATP-production or muscle-bioenergetics trial for deflazacort was found in this review; this is a single animal study finding, not independently replicated.

Population evidence

PMID 33228255 (Int J Mol Sci 2020) reports deflazacort administration was "found to improve mitochondrial respiration of mdx mice due to an increase in the level of ETC complexes (complexes III and IV and ATP synthase), which may contribute to the normalization of ATP levels in the skeletal muscle." A separate rat diaphragm study, "Rat diaphragm contractility and histopathology are affected differently by low dose treatment with methylprednisolone and deflazacort" (Eur Respir J 1995, PMID 7656957), examined myosin adenosine triphosphatase (contractile-protein ATPase, a distinct biochemical process from mitochondrial ATP synthesis) alongside deflazacort's effects on tetanic tension, providing tangential but not directly overlapping context.

Mechanism

Increased abundance of respiratory-chain complexes III and IV and of ATP synthase in dystrophic skeletal muscle following deflazacort treatment, as reported in the source study.

Counter-evidence held on record

This entry shares its primary source with the Mitochondrial burden entry above (see Overlap map); it is not independent confirmation of that entry. It should not be read as evidence that deflazacort improves human energy metabolism or that ATP-related supplementation is warranted.

Limits on what this shows

• Key negative/null findings: Two dedicated PubMed searches this session, "deflazacort" AND (polycythemia OR erythrocytosis OR hematocrit) and "deflazacort" AND "red blood cell," both returned zero results, confirmed directly. No deflazacort-specific hematologic signal in either direction was found.
• At-risk subgroups: Not established for deflazacort; the human evidence located is limited to endogenous Cushing disease, not exogenous drug treatment, an important distinction disclosed here.
• Counter-evidence: This is animal and endogenous-hypercortisolism evidence, not a deflazacort human trial. The Cushing-disease finding reflects chronic endogenous cortisol excess, a different exposure pattern from intermittent or dose-limited exogenous deflazacort therapy, and should not be read as proof that deflazacort itself raises hematocrit in DMD patients. This is a reverse-direction (potentiation) finding, not a depletion signal, and per Hard Rule 5 must not be read as license for iron or erythropoietin-adjacent supplementation.

Population evidence

Three sources independently opened this session. (1) Tang JI, Seckl JR, Nyirenda MJ. "Prenatal Glucocorticoid Overexposure Causes Permanent Increases in Renal Erythropoietin Expression and Red Blood Cell Mass in the Rat Offspring." Endocrinology 2011, PMID 21540288. Dexamethasone administered during the final week of rat gestation; renal erythropoietin mRNA and plasma concentration increased nearly 100% in newborn and adult offspring, with elevated RBC count, hematocrit, hemoglobin, and reticulocytes persisting to 9 months of age. (2) "Erythropoietic action of dexamethasone on the anemia associated with an experimental chronic renal failure." Acta Physiol Pharmacol Latinoam 1987, PMID 3503475. Dexamethasone combined with erythropoietin produced a pronounced increment in hemoglobin, hematocrit, and circulating reticulocytes in a rat renal-failure model; the source states dexamethasone "may stimulate erythropoiesis...through a previous augmentation of erythropoietin." (3) Varricchio L, et al. "Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis." Haematologica 2022, PMID 35861015. Human study: active Cushing disease patients (endogenous hypercortisolism) showed erythrocytosis with normal hemoglobin F and a distinct CD34+/CD110+/CD36+/CXCR4+ progenitor population; ex vivo culture of these cells produced comparable erythroid precursor numbers whether or not dexamethasone was added, and the abnormality resolved after disease remission.

Mechanism

Glucocorticoid-receptor-mediated upregulation of renal erythropoietin expression, and a constitutively glucocorticoid-responsive erythroid progenitor population, demonstrated with dexamethasone and with endogenous hypercortisolism; plausible by class extension to deflazacort as a glucocorticoid-receptor agonist, though not independently demonstrated for deflazacort itself.

Counter-evidence held on record

This is class-level, reverse-direction mechanistic evidence built from dexamethasone-specific animal data and an endogenous-hypercortisolism human disease model, not a deflazacort-specific measurement. It should not be read as evidence that deflazacort itself measurably changes hemoglobin, hematocrit, or oxygen delivery in DMD patients, nor as grounds for any hematologic supplement or intervention.